ABSTRACT
Objective:To analyze the expression of histone methyltransferase SETD1A and SETD5 in breast cancer and its correlation with the clinicopathological characteristics of patients.Methods:A total of 80 breast cancer patients were included in the study. GSCA website screened SET domain family members, predicted their expression in breast cancer tissues, and verified them with immunohistochemical SP method. Chi-square test and Logistic regression model were used to analyze the correlation between SETD1A, SETD5 and clinicopathological characteristics of patients.Results:The GSCA website showed that the expressions of SETD1A and SETD5 of the SET domain family were up-regulated in breast cancer tissues compared with normal tissues (all P<0.05). Immunohistochemical SP method showed that the positive expression rates of SETD1A and SETD5 in breast cancer tissues were 73.8% and 68.8% respectively, which were significantly higher than the positive expression rates of SETD1A and SETD5 in paracancerous tissues 38.8% ( χ2=19.91, P<0.001) and 32.5% ( χ2=21.03, P<0.001). Chi-square test results showed that the expression of SETD1A was significantly correlated with lymph node metastasis and vascular invasion, and the expression of SETD5 was significantly correlated with nerve invasion (all P<0.05). Logistic regression model showed that SETD1A expression was correlated with lymph node metastasis ( OR=0.07, 95% CI: 0.01-0.25, P<0.001) and molecular type ( OR=0.04, 95% CI: 0.00-0.48, P=0.022), SETD5 expression was correlated with neural invasion ( OR=6.41, 95% CI: 1.45-46.65, P=0.029) . Conclusion:The expressions of histone methyltransferases SETD1A and SETD5 are up-regulated in breast cancer tissues, and they are correlated with pathological features such as lymph node metastasis, vascular invasion, and neural invasion.